retatrutide phase 3 trial results Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal obesity In TRIUMPH-1, participants on 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks with glp 1 resistance Anti-Inflammatory cat:weight-management Colour:River Rock

retatrutide phase 3 trial results Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal obesity In TRIUMPH-1, participants on 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks with glp 1 resistance Anti-Inflammatory cat:weight-management Colour:River Rock

glp 1 resistance Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes JCI Insight - Cycling GLP-1 –

Manufacturing biosimilar products involves highly complex biological production processes, extensive analytical characterization, and comprehensive clinical evaluation to demonstrate comparability with the reference product

cat:weight-management

Colour:River Rock

Reduced insulin and IGF-I signaling, not hyperglycemia, underlies the diabetes-associated depletion of interstitial cells of Cajal in the murine stomach